Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (NASDAQ: PODD) is a Massachusetts-based medical device company known for its Omnipod tubeless insulin pump platform, which is designed to simplify life for people with diabetes. The Insulet news feed on Stock Titan aggregates company announcements, earnings updates, product milestones, and strategic disclosures that shape the PODD stock narrative and the evolution of automated insulin delivery.
Investors and observers can follow news on the Omnipod Insulin Management System and the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors to automate insulin dosing without multiple daily injections or fingersticks. Company releases highlight regulatory clearances, such as FDA 510(k) decisions for Omnipod 5 algorithm enhancements, as well as technology demonstrations at events like the Consumer Electronics Show, where Insulet presents its vision for “liveable technology” in connected health.
The PODD news stream also covers quarterly and annual financial results, long-range financial outlooks, and Investor Day presentations in which Insulet outlines its growth strategy in automated insulin delivery markets. Additional updates include sustainability initiatives like the expansion of the U.S. Pod recycling program, collaborations such as the Omnipod Mango color partnership with Pantone, and governance developments including executive and board appointments.
By reviewing Insulet news on this page, readers can track how the company’s Omnipod platform, innovation roadmap, financial performance, and corporate actions intersect. Bookmark this feed to monitor new product features, regulatory developments, strategic events, and other disclosures that may be relevant to understanding PODD as both a medical technology business and a publicly traded stock.
Summary not available.
Insulet Corporation (NASDAQ: PODD) announced its participation in the 45th Nasdaq Investor Conference on December 3, 2021, at 11:30 a.m. ET. The presentation will be held virtually, and investors can access the live webcast at investors.insulet.com/events, with a replay available post-event. Insulet is renowned for its tubeless insulin pump technology through its Omnipod product line, focusing on simplifying diabetes management with its innovative, needle-free delivery system.
Insulet Corporation (NASDAQ: PODD) reported strong third-quarter results for the period ending September 30, 2021, with revenues of $275.6 million, reflecting a 17.8% year-over-year increase. Notably, Omnipod revenue surged to $260.3 million, a growth of 22.7%. Operating income reached $33.7 million with a gross margin of 68.5%. Despite a 30.1% decline in Drug Delivery revenue, net income rose to $12.6 million. The company also updated its revenue guidance for the year to 18%-20% growth and confirmed a low double-digit operating margin expectation.
Summary not available.
Insulet Corporation (NASDAQ: PODD) has appointed Luciana Borio, M.D., to its Board of Directors, bringing extensive government and public health experience. Dr. Borio has held significant roles at the FDA and National Security Council, specializing in medical product development and biodefense. Her expertise is expected to enhance Insulet's growth strategy. Additionally, Sally W. Crawford will retire from the Board effective December 31, 2021, after 13 years of service, with gratitude expressed for her contributions.
Insulet Corporation (NASDAQ: PODD) reported positive results from its pivotal trial extension for the Omnipod 5 Automated Insulin Delivery System, demonstrating significant improvements in diabetes management for users aged 6-70. Over 12 months, participants showed sustained reductions in HbA1c, with adults decreasing from 7.2% to 6.8% and children from 7.7% to 7.0%. Additionally, time in range increased notably. Insulet also presented data on the Omnipod DASH, highlighting a decrease in hypoglycemic events. The Omnipod 5 is expected to launch in the US in late Q4 2021.
Insulet Corporation (NASDAQ: PODD) announced its plan to release third quarter financial results on November 4, 2021, after market close. Management will hold a conference call at 4:30 p.m. ET to discuss the results. Insulet is known for its innovative Omnipod insulin management system, which offers a needle-free, wearable insulin delivery option. The company aims to simplify life for people with diabetes through its unique product platform. Investors can access the call via the company's Investor Relations website.
Insulet Corporation (NASDAQ: PODD) will present at three virtual investor conferences: the Wells Fargo Healthcare Conference on September 9, the Morgan Stanley Global Healthcare Conference on September 10, and the Baird Global Healthcare Conference on September 15, 2021. Each presentation will be accessible via live webcasts, which will also have replays available afterwards. Insulet specializes in innovative diabetes management technology, specifically its Omnipod tubeless insulin delivery system, designed to simplify life for individuals with diabetes.
Insulet Corporation (NASDAQ: PODD) has received FDA clearance to use Eli Lilly's Lyumjev® (insulin lispro-aabc) with its Omnipod® Insulin Management System. Insulet is the only U.S. insulin pump manufacturer authorized for this use, enhancing flexibility for diabetes management. Lyumjev, a rapid-acting insulin, improves post-meal glucose control and is effective when delivered via continuous subcutaneous insulin infusion. This collaboration with Lilly aims to simplify diabetes care by providing more options for insulin administration.
Insulet Corporation (NASDAQ: PODD) announced the upcoming launch of the Omnipod DASH Insulin Management System in Australia at the Australasian Diabetes Congress. Orders are expected to be taken by the end of August. The Omnipod DASH is the first waterproof, tubeless insulin pump in Australia, designed to provide insulin therapy for up to 72 hours. This launch is part of Insulet’s global expansion strategy, which previously included markets in Europe and the Middle East. The new system aims to simplify diabetes management with its intuitive design and customer-centric business model.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
